Search - tctmd.com

Displaying 121 - 140 of 414

Sort: Relevancy | Date

Smart Scale Better at Predicting HF Events Than Weight-Based Monitoring

News Conference News THT 2024

Smart Scale Better at Predicting HF Events Than Weight-Based Monitoring

Michael O'Riordan

March 11, 2024

ACC Updates HFrEF Decision Pathway, Reinforcing the Four Pillars of Therapy

News Daily News

ACC Updates HFrEF Decision Pathway, Reinforcing the Four Pillars of Therapy

March 11, 2024

Small Study Hints at Potential for HF Bone Marrow Cell Therapy: CardiAMP-HF

News Conference News THT 2024

Small Study Hints at Potential for HF Bone Marrow Cell Therapy: CardiAMP-HF

Michael O'Riordan

March 08, 2024

Small Study Hints at Apixaban’s Potential in LVAD-Treated Patients

News Conference News THT 2024

Small Study Hints at Apixaban’s Potential in LVAD-Treated Patients

Michael O'Riordan

March 07, 2024

Durable 1-Year Outcomes With Coronary Sinus Shunt for HF: ALT-FLOW EFS

News Conference News THT 2024

Durable 1-Year Outcomes With Coronary Sinus Shunt for HF: ALT-FLOW EFS

Michael O'Riordan

March 06, 2024

PH-HFpEF: Levosimendan

Presentation THT 2024

PH-HFpEF: Levosimendan

Presenter: Sanjiv J. Shah

March 06, 2024

Disparities in Guideline Directed Medical Therapy (GDMT) Use and Dosing in Rural (versus Non-Rural) Veterans with Heart Failure with Reduced Ejection Fraction (HFrEF)

Presentation THT Abstracts 2024

Disparities in Guideline Directed Medical Therapy (GDMT) Use and Dosing in Rural (versus Non-Rural) Veterans with Heart Failure with Reduced Ejection Fraction (HFrEF)

Presenter: Alexandra Steverson

March 05, 2024

Debating the Role of T-TEER in the Sickest Patients

News Conference News THT 2024

Debating the Role of T-TEER in the Sickest Patients

Michael O'Riordan

March 05, 2024

A Case of Severe De Novo HF on Support for 14 days Without Evidence of Recovery

Presentation THT 2024

A Case of Severe De Novo HF on Support for 14 days Without Evidence of Recovery

Presenter: Elena M. Donald

March 04, 2024

FDA-Approved But Less Frequently Used Device Therapies to Treat HFrEF: Challenges and Opportunities

Presentation THT 2024

FDA-Approved But Less Frequently Used Device Therapies to Treat HFrEF: Challenges and Opportunities

Presenter: Michael R. Zile

March 04, 2024

March 2024 Dispatch for the CV Team

News Opinion CV Team Dispatch

March 2024 Dispatch for the CV Team

March 01, 2024

More Mortality Reduction Signals With Implantable Hemodynamic Monitors in HFrEF: Meta-analysis

News Daily News

More Mortality Reduction Signals With Implantable Hemodynamic Monitors in HFrEF: Meta-analysis

February 12, 2024

February 2024 Dispatch for the CV Team

News Opinion CV Team Dispatch

February 2024 Dispatch for the CV Team

February 01, 2024

GDMT Rates Low in HFrEF, Particularly in Women

News Daily News

GDMT Rates Low in HFrEF, Particularly in Women

January 30, 2024

CRT-D Offers Persistent Survival Benefit in Long-term RAFT Results

News Daily News

CRT-D Offers Persistent Survival Benefit in Long-term RAFT Results

January 23, 2024

January 2024 Dispatch for the CV Team

News Opinion CV Team Dispatch

January 2024 Dispatch for the CV Team

January 01, 2024

The Biggest News of 2023: TCTMD’s Top 10

News Opinion Editor's Corner

The Biggest News of 2023: TCTMD’s Top 10

January 01, 2024

STRONG-HF: Higher GDMT Doses Equal Better Outcomes

News Daily News

STRONG-HF: Higher GDMT Doses Equal Better Outcomes

December 29, 2023

AHA Selects 2023’s Leading Cardiovascular Research

News Daily News

AHA Selects 2023’s Leading Cardiovascular Research

December 22, 2023

Who Benefits Most From Semaglutide and How Long Will That Take?

News Daily News

Who Benefits Most From Semaglutide and How Long Will That Take?

December 19, 2023

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.